Ask the Experts
Nazim Kanji is the Executive Director of Pediatric Services at Quotient Sciences. In his current role, Nazim works closely with clients to help them scope their pediatric development programs. He also provides ongoing technical support and expertise related to pediatric formulation to the entire Quotient Sciences product development team.
Nazim has over 25 years of experience in the pharmaceutical and consumer healthcare industries, where he has worked in product development roles with Boots Pharmaceuticals, Boots Healthcare International, and Reckitt Benckiser. Nazim's experience includes taking products from the concept stage through to commercialization.
Prior to joining Quotient Sciences, Nazim was Co-owner and Director of Co-Formulate, a contract formulation development organization acquired by Quotient Sciences in 2015. He holds a Bachelor of Pharmacy from the University of Nottingham.
Quotient Sciences and Kadmon (a Sanofi company) presented a poster at the European Pediatric Formulation Initiative (EuPFI) conference in September 2021, describing a program that was carried out by Quotient Sciences to develop a pediatric formulation for belumosudil, a ROCK2 selective inhibitor developed by Kadmon for the treatment of immune disorders. The aim was to develop a new oral suspension formulation using age-appropriate excipients suitable for patients aged between 3 months and 12 years, which could be taken forward into a relative bioavailability assessment versus the reference adult tablet formulation.